<DOC>
	<DOC>NCT02837198</DOC>
	<brief_summary>To investigate the pharmacodynamics, pharmacokinetics and safety of 7-day-repeated doses of FYU-981 administered orally to male hyperuricemic patients with uric acid-overproduction or uric acid-underexcretion type. In addition, to investigate the additive effects of the combination of FYU-981 and topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction type.</brief_summary>
	<brief_title>Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Japanese adult subjects Serum urate level: &gt;= 7.0mg/dL in patients Disease Type: Uric acidoverproduction Type or Uric acidunderexcretion Type Gouty arthritis within a year before start of study treatment Mixed type in the classification of hyperuricemia</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>